白衣効果と高血圧の動脈硬化に対する相互作用
Lin Jin1, Zhenyi Li1, Xinyi Li2,3
1Department of Ultrasound, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine.
Journal of hypertension
|February 6, 2026
まとめ
白衣効果(WCE)は、高血圧患者の動脈硬化の増加と心血管疾患(CVD)リスクの上昇に関連している。この研究では、WCEが動脈硬化を独立して予測し、特に女性においてその傾向が強いことがわかった。
科学分野:
- 循環器病学
- 高血圧研究
- 血管生物学
背景:
- 臨床設定における血圧上昇を特徴とする白衣効果(WCE)は、議論のある心血管疾患(CVD)リスク因子です。
- WCE、高血圧、および動脈硬化の関連に関する既存の研究は一貫性がなく、さらなる調査が必要とされています。
研究 の 目的:
- 動脈硬化に関するWCEと高血圧の相互作用を調査すること。
- WCEが動脈硬化およびCVDリスクの独立した予測因子であるかどうかを判断すること。
主な方法:
- 対照群および高血圧患者を含む7584人の参加者のコホートは、対照群、白衣高血圧(WCH)、高血圧、および白衣性管理不能高血圧(WUCH)の4つのグループに分類されました。
- 動脈硬化は、カフオシロメトリーによる脈波伝播速度指数(AVI)および動脈圧容積指数(API)を使用して評価されました。
- ロジスティック回帰および制限立方スプライン(RCS)分析を用いて、リスク因子およびAPI-脈圧関係を評価しました。
主要な成果:
- WUCHの参加者は、WCHと比較して高齢であり、より高い脈圧(PP)およびAPIを示しました。
- WCH/WUCHおよびAPIの両方が、動脈硬化の独立した決定因子および高CVDリスクの有意な予測因子として多変量解析で特定されました。
- WCEおよび非WCE個人の両方で、APIとPPの間に有意なJ字型の関係が観察されました。
結論:
- 白衣効果を経験した個人は、末梢動脈硬化の増加を示し、女性においてより顕著な効果が認められました。
- 本研究は、WCEがCVDリスクの上昇に関連する独立した危険因子であることを確認しました。
- 動脈硬化指数(API)と脈圧(PP)の間のJ字型の関連は、WCEの状態に関係なく存在する可能性があります。
関連する概念動画
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
477
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
512
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
628
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
628
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
Hypertension I: Introduction
911
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
911


